PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an update.
PYC Therapeutics Limited has successfully raised $9.3 million through the retail component of its Accelerated Non-Renounceable Entitlement Offer, contributing to a total of approximately $100 million raised so far. The total funding goal of $146 million will enable PYC to advance its pipeline of four first-in-class drug candidates with disease-modifying potential, addressing areas of major unmet patient need. This financial boost is expected to significantly impact PYC’s operations by facilitating multiple human efficacy read-outs, potentially enhancing its position within the rapidly growing RNA therapeutic industry.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company leverages its proprietary drug delivery platform to enhance the potency of precision medicines, specifically targeting monogenic diseases, which have a higher likelihood of success in clinical development.
YTD Price Performance: -5.34%
Average Trading Volume: 443,724
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$723.2M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.